ATLANTA, GA - Registration is now open for the upcoming Tribe Public CEO Presentation and Q&A Webinar featuring GeoVax Labs Chairman & CEO David Dodd. The event, titled "Ebola, Marburg, Hantavirus, Mpox and Beyond: Building a Resilient Infectious Disease Preparedness Strategy," is scheduled for May 28, 2026, at 8:00 a.m. Pacific Time / 11:00 a.m. Eastern Time.
GeoVax Labs, Inc. (Nasdaq: GOVX), a clinical-stage biotechnology company specializing in vaccines and immunotherapies for infectious diseases and cancer, announced that Dodd will participate in the webinar hosted by Tribe Public, a San Francisco-based firm that facilitates corporate-sponsored global webinars and investor engagement events. The discussion aims to address critical gaps in global biodefense infrastructure and the need for versatile vaccine platforms.
Echoing concerns raised by recent outbreaks of Ebola, Marburg, Mpox, and Hantavirus, Dodd stated, "Global preparedness strategies must evolve beyond reactive, single-threat approaches." He emphasized that GeoVax is focused on advancing MVA-based vaccine technologies designed to support broader infectious disease preparedness. The company's priority program, GEO-MVA, is a Modified Vaccinia Ankara (MVA)-based vaccine targeting mpox and smallpox, which is advancing under an expedited regulatory pathway with plans to initiate a pivotal Phase 3 clinical trial in the second half of 2026.
The webinar is expected to cover several key topics, including the growing importance of platform-based vaccine technologies, why emerging outbreaks continue to expose vulnerabilities in response infrastructure, the potential applicability of MVA-based technologies across multiple viral threats such as orthopox and hemorrhagic fever viruses, and the importance of scalable and resilient domestic vaccine manufacturing capabilities.
Participants can register for the complimentary Zoom webinar event at Ebola-May-2026.TribePublic.com. Once registered, attendees may submit questions in advance to research@tribepublic.com or use Zoom's chat feature during the live event. Tribe Public Managing Member John F. Heerdink, Jr. will host and moderate the audience Q&A.
This announcement comes as GeoVax continues to develop its infectious disease and oncology programs. In addition to GEO-MVA, the company is developing Gedeptin®, a gene-directed enzyme prodrug therapy (GDEPT) designed to enhance immune checkpoint inhibitor activity, which has completed a Phase 1/2 clinical trial in advanced head and neck cancer. GeoVax maintains a global intellectual property portfolio and is evaluating strategic partnerships and funding opportunities.
The webinar underscores the critical need for a resilient infectious disease preparedness strategy, as highlighted by recent viral outbreaks. Dodd's presentation will provide insights into how MVA-based technologies could play a pivotal role in addressing current and future threats, potentially impacting global biodefense and vaccine manufacturing capabilities. For more information about GeoVax, visit www.geovax.com.
